Savior Lifetec

Savior Lifetec EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Savior Lifetec (4167.TWO) as of Oct 25, 2026 is 198.24 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 118.90 M TWD — a change of 66.73% (higher).

EBITDA

198.24 MTWD

YoY

66.73%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Savior Lifetec is 2025 198.24 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Savior Lifetec was 2024 118.90 M TWD. It decreases by 66.73% higher compared to the previous year.

The Savior Lifetec EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-350.27 M TWD
Jan 1, 2019
34.18 M TWD
Jan 1, 2020
287.05 M TWD
Jan 1, 2021
27.32 M TWD
Jan 1, 2022
52.00 M TWD
Jan 1, 2023
-2.42 M TWD
Jan 1, 2024
118.90 M TWD
Jan 1, 2025
198.24 M TWD
The Savior Lifetec EBITDA history
YEAREBITDAYoY
198.24 MTWD+66.73%
118.90 MTWD-5,013.22%
-2.42 MTWD-104.65%
52.00 MTWD+90.34%
27.32 MTWD-90.48%
287.05 MTWD+739.84%
34.18 MTWD-109.76%
-350.27 MTWD-812.37%
49.17 MTWD-128.68%
-171.41 MTWD-62.92%
-462.33 MTWD+39.68%
-331.00 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Savior Lifetec Stock analysis

What does Savior Lifetec do? Savior Lifetec Corp develops, produces, and sells active pharmaceutical ingredients and finished dosage formulations, including Meropenem, Imipenem/Cilastatin, and Ertapenem, which are used as broad-spectrum antibiotics. The company provides APIs intermediates and bio-pharmaceutical technology services, distributing its products to Europe, the Americas, Asia, and other global markets. Its primary revenue streams come from the sale of pharmaceutical products and technology services to international markets. The company's product portfolio focuses on antibiotics such as Meropenem and Ertapenem, which are sold as finished dosage formulations. APIs intermediates are supplied to clients in the pharmaceutical industry, while bio-pharmaceutical technology services support clients in drug development and manufacturing. These offerings target global pharmaceutical companies seeking reliable supply chains and technical expertise. Savior Lifetec Corp's customers include pharmaceutical firms in Europe, the Americas, Asia, and other regions that require active pharmaceutical ingredients and specialized technology services. The company generates revenue through direct sales of its antibiotic formulations and API intermediates, as well as through contractual agreements for bio-pharmaceutical technology services. Savior Lifetec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Savior Lifetec stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Savior Lifetec is 198.24 M TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Savior Lifetec changed from 118.90 M TWD to 198.24 M TWD, representing a 66.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Savior Lifetec since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Savior Lifetec historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Savior Lifetec

All Key Metrics — Savior Lifetec